Metabolic Signatures: Unraveling Disease Pathways with NMR* Metabolomics and Lipoprotein Insights
Bruker: Metabolic Signatures: Unraveling Disease Pathways with NMR* Metabolomics and Lipoprotein Insights
Join an inspiring session on Wednesday, May 8th, 2024, at 5 PM CET with academic key opinion leaders as they are sharing insight about NMR-based metabolomics combined with insights into lipoproteins and their subclasses in disease research. Prof Tone Bathen and Dr. Christoph Trautwein will present findings from their studies in infectious diseases and cancer research, highlighting key insights into the analytical process aimed at identifying prognostic and predictive biomarkers.
Discover the transformative potential of NMR-based metabolomics coupled with insights into lipoproteins and their subclasses in disease research and cancer stratification. This webinar illuminates the power of standardized NMR-based metabolomics to comprehensively detect and quantify metabolites, offering invaluable insights into the molecular mechanisms of health and disease. By exploring the intricate interplay between metabolomics and lipoprotein biology, we aim to uncover robust biomarkers for enhanced diagnosis, prognosis, and treatment stratification in cancer and various pathologies. Join us as we delve into the dynamic molecular landscape of disease, paving the way for personalized medicine and improved patient outcomes.
Key Learning Points
- NMR-based metabolomics emerges as a pivotal omics tool in disease investigation.
- Emphasizing standardization and reproducibility becomes crucial in clinical research, laying the foundation for effective clinical translation
- Throughout the cancer trajectory—from prognosis to risk assessment and therapy monitoring—NMR-based metabolomics holds the potential to furnish vital insights
- Lipoproteins, small molecules, and modified glycoproteins present promising avenues for cancer sub-stratification, enhancing the precision of patient care and facilitating personalized therapeutic interventions.
Who Should Attend
- Cinical researchers: Biologists, biochemists, and analytical scientists investigating or interested in expanding research into metabolic diseases, cancer, cardiovascular disorders, and related fields.
- Omicists: Professionals working in human metabolomics research seeking to expand their expertise into standardized NMR-based Metabolomics.
- Graduate students and postdoctoral fellows: Those seeking to gain advanced knowledge and practical skills in applying NMR in human health, metabolic disease, and cancer research
- Industry professionals: Scientists and R&D personnel in pharmaceutical, biotechnology, and nutritional companies doing research and developing therapeutic and diagnostic solutions related to metabolic health.
Presenter: Prof. Dr. Tone Frost Bathen (Professor at NTNU-Norwegian University of Science and Technology - Dept. of Circulation and Medical Imaging)
Since 2006, Prof. Tone Frost Bathen has worked at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway, where she currently leads the Magnetic Resonance Cancer Group. The group’s main interests are focused on personalized medicine and studies of functional and metabolic properties of cancer, using magnetic resonance imaging, positron emission tomography, and magnetic resonance spectroscopy, more commonly referred to as NMR. Currently, Prof. Bathen’s research activities focus on breast and prostate cancer and establishing better diagnostic tools for stratification of patients to treatment and treatment monitoring
Presenter: Dr. Christoph Trautwein (Group Leader Metabolomics and Systems Medicine, at Werner Siemens Imaging Center at the University of Tübingen)
Dr. Christoph Trautwein studied Environmental Engineering at the University of Stuttgart, Germany, before starting in 2007 a second career in Molecular Medicine at the University of Freiburg, where he also completed his PhD. After a postdoc at the Karlsruhe Institute of Technology, in 2017 he joined the Werner Siemens Imaging Center at the University of Tübingen, where he currently leads the research group for Metabolomics & Systems Medicine.